Skip to main content

You are here

IGF Oncology


Blood Cancer Drug in Clinical Trails at Mayo Clinic

Investment Opportunity

IGF Oncology develops targeted cancer chemotherapy drugs that offer reduced side effects and improved effectiveness, as compared to existing chemotherapy treatments. IGF's lead drug, IGF-MTX, targets the deadly blood cancer MDS, and is currently in clinical trials at the Mayo Clinic. 


  • The IGF founder is a Ph.D. biochemist, patent attorney, and cancer survivor; the perfect candidate to found a biotech cancer company. 
  • An investment in IGF has the potential for significant growth, as shares are currently being offered at a valuation of just $10 million, while the company's lead drug boasts the potential for annual revenue of over $200 million. 
  • IGF’s patented lead drug, IGF-MTX, targets MDS cancer cells specifically, with very low side effects, and has already proven successful in animal testing and in a human clinical trial.
  • IGF-MTX is now in clinical trials at the Mayo Clinic treating the deadly blood cancer (MDS).
  • IGF-MTX is unique in that it causes zero decrease in white blood cell counts. This is crucial since MDS patients already suffer from low white blood cell counts and further reduction can be fatal.
  • In addition to it's ability to bind more specifically to cancer cells, IGF-MTX causes cancer cells to divide, making them more vulnerable and easier to attack.

We are offering a discounted unit price to early investors on a first come, first served basis. All capacity at the previous unit price of $2.00 has been filled.

Invest now to lock your position at the current discounted unit price of $2.05 (Limited capacity available).



Dear prospective investor,

My name is Hugh McTavish, I am a cancer survivor, patent attorney, Ph.D. biochemist, and the founder and CEO of IGF Oncology.

During my fight with cancer I created a better way to treat it, and quickly patented my ideas leading to the formation of IGF Oncology.

My invention, IGF-MTX, fights the blood cancer Myelodysplastic Syndrome or “MDS”. The current drugs used to fight MDS are not very effective, and normal chemotherapy drugs like Methotrexate cannot be used because they dramatically lower the white blood cell count, which can be fatal to MDS patients because they already suffer from very low blood counts as a result of their disease.

By attaching our patented Insulin-like growth factor variant protein to Methotrexate, we have created IGF-MTX. It has proven to alleviate the issues with decreased white blood cell counts found with previous drugs. Moreover, it is more effective than methotrexate, even at a 12x lower dose. This is because the treatment binds more specifically to cancer cells and causes them to divide, making them more vulnerable to be killed.

So far IGF has had successful animal trials and a successful human trial. We are currently conducting clinical trials at the Mayo Clinic working toward our FDA approval.

Key Investment Highlights

  • Market Size

    We estimate the revenue potential for our lead drug is $200 million per year. IGF’s second drug, CPE, is projected to generate $200 million per year of revenue in the ovarian cancer market if approved. Making the total market size around $400 Million annually.   At a current valuation of around $10 million, reaching this revenue potential would create a rise in the company's valuation.  Just last month Roche bought Florida's Flatiron Health for $1.9 billion, which is around the price IGF could be valued at if it were to reach its revenue potential.   Many following the sector are calling for M&A activity to pick up, which is another factor moving in IGF's favor.

  • Significantly Improved Side Effect Profile

    The IGF-MTX drug has very few chemotherapy-type side effects. In particular, it causes NO decrease in blood cell counts. This is crucial for MDS blood cancer because MDS patients already have low blood cell counts, and cannot tolerate any further decrease.  There is NO current MDS treatment or drug that comes close.

  • Proof of Concept

    IGF-MTX is more effective than methotrexate in animal models of cancer even at 6-fold lower dose.

  • How it Works

    It binds to a target, the IGF receptor, that is at found at high levels on MDS blood cancer cells and is quite specifically expressed in MDS blood cancer cells as opposed to healthy bone marrow cells. It kills MDS blood cancer cells in the lab.

  • Competitive Advantage

    Our patent position is very strong. We have several issued patents that cover this drug and will not expire until 2035. We also have a pending patent application on methods of treatment with the drug that we expect will provide further patent protection to 2038.

  • Mayo Clinic

    The company's IGF-MTX drug is being tested in clinical trials at the world-famous Mayo Clinic.



IGF Oncology

Post Offering Valuation - $10,000,000

Target Capital Raise - $2,250,000

Minimum Per Investor - $1,000

Price Per Share - $2.00 - $2.50


We are offering a minimum investment of $1,000, with a goal to raise up to $2.25 Million. If you are interested in joining, please click the “Invest Now” button. There are several investment levels being offered between $2.00 and $2.50 per share. It is being offered on a first come first served basis.

This investment is offered to investors worldwide

IGF Drug Summary

Lead Drug IGF-MTX

• Insulin-like growth factor variant protein attached to the chemotherapy drug methotrexate.
• Targets a receptor protein, IGF-1R, overexpressed on cancer, so it is a targeted chemotherapy that selectively targets and kills cancer cells and has less effect on healthy cells.
• Approximately 13 times more effective than methotrexate in mouse model of solid tumor cancers.

Phase 1 human clinical trial results: 

• Effective at a surprisingly low dose, about 12 times lower dose than the minimum dose methotrexate is usually used at.
• One Hodgkins lymphoma patient whose cancer progressed on standard drugs is now cancer free after treatment with IGF-MTX.
• Efficacy in three other solid tumor patients.
• ZERO decrease in blood cell counts, the most important side effect of standard chemotherapy.
• Opening a Phase 2a clinical trial at Mayo Clinic in the blood cancer myelodysplastic syndrome (MDS) in January 2018.
• MDS is a deadly blood cancer with no very effective treatments.
• Only two currently approved drugs for MDS, and they don’t work very well.
• IGF-MTX kills MDS cells in the laboratory and is synergistic with the most commonly used of two approved drugs.
• IGF receptors are overexpressed on MDS disease cells.
• IGF-MTX is well suited for this disease because the patients cannot tolerate any decrease in blood cells, and unlike all other cancer chemotherapy, IGF-MTX does not cause any decrease in blood cells.

Second drug: CPE-54

• An engineered food poisoning toxin.
• Binds to a target overexpressed on ovarian cancer and other cancers.
• Well suited for late stage ovarian cancer because it kills late stage ovarian cancer cells better than early stage, unlike all other drugs.
• Clinical trial planned to begin in 2018.

Intellectual Property Summary

US Patent No. 7,811,982 and family covering 765IGF-MTX

IGF Oncology owns U.S. Patent No. 7,811,982, which claims broadly variants of IGF-1 conjugated to anti-cancer chemotherapeutic agents. The variants of IGF-1 are those with reduced binding affinity for the soluble IGF-binding proteins. The claims encompass but do not name or disclose the 765IGF variant and the 765IGF-MTX conjugate. Methotrexate is specifically claimed as a chemotherapeutic agent portion of the conjugate. This patent has a 770 day extension for USPTO delays, and so expires in about December 2026, with further extensions of time available for time in clinical trials and FDA approval. Other patents in this family are US Patent Nos. 9,011,880 and 8,501,906. We have issued foreign patents in this family in Canada, UK, France, Germany, and Japan.

U.S. Patent No. 9,675,671 and family covering 765IGF-MTX and 765EGF-bendamustine

This patent is directed to the 765IGF protein and the 765EGF protein, which are our proprietary variants of IGF-1 and EGF respectively, and it covers other cytokines with the same or related N-terminal segment as is used in 765IGF and 765EGF. This patent will expire on January 12, 2035, with extensions possible for time spent in clinical trials and FDA review. An allowed divisional U.S. patent claims the chemotherapeutic conjugates to 765IGF and 765EGF, specifically including 765IGF-MTX and 765EGF-bendamustine. Foreign patent applications in this family are filed in Japan, India, Korea, Canada, Australia, and Europe.

U.S. Patent Nos. 8,017,102 and family

This patent claims conjugates of toxins (as contrasted with chemotherapeutic agents) with variants of IGF-1 having reduced binding affinity for the soluble IGF-binding proteins. The other patent in this family is U.S. Patent No. 8,920,777. We have issued foreign patents in UK, Germany, and France in this family.

U.S. Provisional patent application 62/509,150, covering method of treatment for using 765IGF-MTX to treat myelodysplastic syndrome.

This provisional patent application will be converted to a regular U.S. utility patent application and international patent application in 2018. When patents are issued on these, they would have patent term extending to at least 2038.

Patent applications to be filed to cover CPE-54 specifically as a composition, and a method of treating cancer

We intend to file patent applications for these two new inventions in 2018. Issued patents based on these would expire in 2038 most likely. These will be assigned to IGF Oncology, LLC.

U.S. Patent No. 8,664,184, and family, licensed from Yale University and the Univ. of Arkansas, covering use of CPE to treat ovarian and uterine cancers and peritoneally located cancers

This patent has claims covering use of CPE to treat ovarian and uterine cancers with CPE or a variant thereof, optionally by peritoneal administration. Other patents in the family are U.S. Patent Nos. 9,702,010, and 8,247,371. They expire on October 12, 2025, with possible extension for time in clinical trials and for FDA approval. U.S. Patent No. 8,247,371 also has a 638 day extension for USPTO delays. These are all licensed from Yale University. U.S. Patent No. 7,927,795 is for diagnosing or monitoring ovarian cancer by detecting overexpression of claudin-3 or -4 or many other genes. It has the same inventor, Dr. Santin, and is assigned to the Univ. of Arkansas and licensed from them.


Hugh McTavish
Ph.D., J.D.,CEO, & Founder

Dr. Hugh McTavish is a practicing patent attorney and a Ph.D. biochemist with extensive experience in the laboratory. He is also the inventor of the company’s technology. Dr. McTavish is the lead author of several refereed scientific publications, and the inventor of several issued patents and pending patent applications. He received his Ph.D. in biochemistry from the University of Minnesota in 1992, and his J.D. from the University of Minnesota in 2001.

Arkadiusz Dudek
M.D., Ph.D., Chief Medical Officer

Arkadiusz Dudek is Professor of Hematology/Oncology and Director of Oncology Clinical Trials at the University of Illinois Chicago.
Dr Dudek has over 18 years of cancer clinical research experience, over 18 years in the clinical management of mesothelioma, lung cancer, kidney cancer, and malignant melanoma, and over 13 years in the field of tumor angiogenesis, signal transduction, and cancer immunotherapy. His expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has 17 years of serving in several leadership positions in clinical trial offices at the University of Minnesota and the University of Illinois. He chairs and manages a broad range of clinical trials (from phase 1 through phase 3, from cooperative group, investigator-initiated, and industry sponsored studies) that are either therapeutic or non-therapeutic studies.

Ronald Way
Board Member

Former U.S. Senate staffer and journalist. Current board member for several medical device and pharmaceutical companies

Kathleen Littrell
Senior Director Clinical Operations

Has more than 20 years experience in all phases of clinical trials.